SMSPHARMA vs ZIMLAB: Stock Comparison

SMS Pharmaceuticals Limited vs Zim Laboratories Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

SMS Pharmaceuticals Limited is the larger company by market capitalisation. SMS Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Zim Laboratories Limited shows faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of SMS Pharmaceuticals Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, SMSPHARMA is more favourable on 10 of 13 scored metrics and ZIMLAB on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SMSPHARMA is the larger company
₹3,560 Cr vs ₹617 Cr
P/E Ratio
SMSPHARMA has a lower P/E
34.95x vs 105.73x
P/B Ratio
ZIMLAB has a lower P/B
2.08x vs 4.54x
EPS
SMSPHARMA has higher earnings per share
₹11.17 vs ₹1.94
Dividend Yield
SMSPHARMA has a higher dividend yield
0.1% vs 0.02%
Revenue Growth (TTM YoY)
ZIMLAB has faster revenue growth
-3.36% vs -4.1%
EPS Growth (TTM YoY)
SMSPHARMA has faster EPS growth
49.2% vs -47.01%
Qtr Sales Growth
SMSPHARMA has stronger quarterly sales growth
-4.13% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSMSPHARMAZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSMSPHARMAZIMLAB
Live Price₹380.75₹104.91
Day Change-2.85%0.25%
Volume1.03 L81,241
52-Week High₹447.8₹115.17
52-Week Low₹207.99₹59.31
Distance from 52W High-14.97%-8.91%

Valuation

MetricSMSPHARMAZIMLAB
Market Cap₹3,560 Cr₹617 Cr
P/E Ratio34.95x105.73x
P/B Ratio4.54x2.08x
EPS₹11.17₹1.94
Book Value₹81.83₹51.77
Dividend Yield0.1%0.02%

Growth

MetricSMSPHARMAZIMLAB
Revenue Growth (TTM YoY)-4.1%-3.36%
EPS Growth (TTM YoY)49.2%-47.01%
Qtr Sales Growth-4.13%-12.3%
Qtr Profit Growth61%-308%

Profitability & Leverage

MetricSMSPHARMAZIMLAB
ROE14.3%1.97%
ROCE13.3%8.16%
Net Margin11.5%1.56%
Operating Margin19.3%5.72%
Debt to Equity0.46x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSMSPHARMAZIMLAB
Promoter Holding68.07%30.36% 0.01 pp
FII Holding0.65% 0.34 pp0.03% 0.03 pp
DII Holding2.83% 0.19 pp1.33% 1.26 pp
Public Holding28.45% 0.15 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SMS Pharmaceuticals Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.